Adicet Bio Announces Formation of Scientific Advisory Board
15 Luglio 2021 - 1:00PM
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer and other diseases, today announced the formation of a
Scientific Advisory Board (SAB). The SAB is comprised of renowned
scientific leaders in the fields of T cell biology, immunology, and
oncology.
"We are very pleased to have such distinguished and talented
experts join Adicet’s scientific advisory board,” said Chen Schor,
President and Chief Executive Officer of Adicet Bio. “The combined
knowledge of our SAB members in translational science and clinical
development as well as their strategic counsel will serve as a
vital resource in advancing the development of our lead asset,
ADI-001, and our pipeline of “off-the-shelf” gamma delta T cell
product candidates.”
Adicet’s SAB members include:
Alice Bertaina, M.D., Ph.D.Dr. Bertaina is an Associate
Professor of Pediatrics - Stem Cell Transplantation in the
department of Stem Cell Transplantation and Regenerative Medicine
and a pediatric hematologist/oncologist at Lucile Packard
Children's Hospital at Stanford University. She is an expert in the
field of allogeneic hematopoietic stem cell transplantation (HSCT)
in pediatric patients affected by hematological malignancies or
nonmalignant disorders. Prior to joining Stanford, she was Head of
the Stem Cell Transplant Unit in the Department of Hematology and
Oncology at the Bambino Gesù Children’s Hospital in Rome. Dr.
Bertaina obtained her M.D. degree at the University of Pavia,
Italy; fellowship in HSCT at the Bambino Gesù Children’s Hospital,
Rome, and Ph.D. degree in Immunology and Biotechnology at Tor
Vergata University in Rome.
Marco Davila, M.D., Ph.D.Dr. Davila is a medical oncologist in
the Department of Blood and Marrow Transplantation at Moffitt
Cancer Center. He is a clinical expert with significant experience
with gene-engineered T cell therapies. Dr. Davila’s clinical focus
is utilizing cell therapies to treat patients with hematologic
malignancies. His research has been acknowledged with grants and/or
awards from the American Society of Hematology, Damon Runyon Cancer
Research Foundation, American Society of Clinical Oncology, and
American Society for Clinical Investigation. Dr. Davila obtained
his M.D. and Ph.D. degrees at the Duke University School of
Medicine and trained in medicine and medical oncology at NY
Presbyterian Weill-Cornell and the Memorial Sloan Kettering Cancer
Center, respectively.
Rupert Handgretinger, M.D.Dr. Handgretinger is Professor
emeritus of Pediatrics. He was the Chairman of the Department of
General Pediatrics and Hematology/Oncology at Children’s University
Hospital, Tübingen, Germany. He is currently working at the Abu
Dhabi Stem Cell Center and Yas clinic Khalifa City. Dr.
Handgretinger’s main research interests have been cellular
immunotherapeutic approaches to the treatment of children with
various forms of cancer. He was one of the first to introduce
immunotherapy with bispecific antibodies in children with
relapsed/refractory acute lymphoblastic leukemia and is also
involved in clinical trials using anti-CD19 and anti-CD19/22 CAR’s
in pediatric R/R ALL. He pioneered the T-cell receptor alpha/beta
depletion technology in allogeneic transplantation. He received his
medical degree from the Eberhard Karls University in Tübingen,
where he completed his training in pediatrics and
hematology/oncology.
Michael Kalos, Ph.D.Dr. Michael Kalos is an internationally
recognized expert in T cell therapy and immunotherapy and brings
over 25 years of experience in the fields of cell therapy,
oncology vaccines, and immune-oncology. Previously, Dr. Kalos was
Executive Vice President and Head of Research and Development at
ArsenalBio. He also served as Vice President, Immuno-oncology and
Oncology Cell Therapies, at Janssen, the Pharmaceutical Companies
of Johnson and Johnson, and chief scientific officer at Eli Lilly
& Company. Dr. Kalos’s academic lab at UPenn played a key role
in the early clinical development of Kymriah, including developing
the methodologies and strategies to enable robust pharmacodynamic
and mechanistic analysis of CAR T therapies. He obtained his Ph.D.
from the University of Minnesota and completed post-doctoral
training in the laboratory of Phil Greenberg at the Fred Hutchinson
Cancer Research Center.
Lloyd Klickstein, M.D., Ph.D.Dr. Klickstein is the Chief
Executive Officer of Versanis Bio. Previously he served as Adicet
Bio’s Chief Innovation Officer since its merger with resTORbio in
September 2020, formerly holding the role of Chief Scientific
Officer of resTORbio. Prior to joining resTORbio, Dr. Klickstein
was Head of Translational Medicine for the New Indication Discovery
Unit (NIDU) and the Exploratory Disease Area (DAx) at Novartis
Institutes for Biomedical Research. Dr. Klickstein received his
B.S. degree from Tufts University, his M.D. and Ph.D. degrees from
Harvard University, completed post-graduate clinical training in
Internal Medicine, Rheumatology & Immunology at BWH and a
post-doctoral research fellowship at the Center for Blood Research
in Boston.
Saul Priceman, Ph.D. Dr. Priceman is Assistant Professor in
the Departments of Hematology and Hematopoietic Cell
Transplantation and Immuno-Oncology at City of Hope Comprehensive
Cancer Center. He is also Associate Director of Translational
Sciences in the T Cell Immunotherapy Program. Over the last 10
years, Dr. Priceman’s research has focused on T cell biology and
clinical translation of cancer immunotherapies. His laboratory
develops CAR based T cell therapies and combinatorial approaches
for the treatment of solid cancers including breast, prostate,
ovarian and pancreas, and has brought several therapies to phase 1
clinical testing. Dr. Priceman’s research has led to high-impact
journal publications in Science Translational Medicine, Cell
Metabolism, Clinical Cancer Research, and Molecular Therapy, with
numerous patents and technologies licensed for further clinical
development. His research has been funded with grants and/or awards
from the Department of Defense, California Institute for
Regenerative Medicine, and the National Comprehensive Cancer
Network. Dr. Priceman received his B.S. in microbiology at
University of California Santa Barbara, and his Ph.D. in molecular
and medical pharmacology at University of California Los
Angeles.
Constantine Mitsiades, M.D., Ph.D.Dr. Mitsiades is Assistant
Professor of Medicine at Harvard Medical School in the Department
of Medical Oncology at Dana-Farber Cancer Institute, and his
research focuses on understanding and overcoming the mechanisms of
tumor cell resistance to pharmacological and immune-based
therapies. He received his M.D., Ph.D., and a master’s degree
in Basic and Clinical Medical Sciences from the University of
Athens, School of Medicine, in Greece. He also received a master’s
degree in Medical Sciences from Harvard Medical School.
About Adicet Bio, Inc.Adicet Bio, Inc. is a
biotechnology company discovering and developing allogeneic gamma
delta T cell therapies for cancer and other diseases. Adicet is
advancing a pipeline of “off-the-shelf” gamma delta T cells,
engineered with chimeric antigen receptors and T cell receptor-like
antibodies to enhance selective tumor targeting, facilitate innate
and adaptive anti-tumor immune response, and improve persistence
for durable activity in patients. For more information, please
visit our website at http://www.adicetbio.com.
Adicet Bio., Inc.Investor and Media
Contacts
Anne Bowdidgeabowdidge@adicetbio.com
Janhavi MohiteStern Investor Relations,
Inc.212-362-1200janhavi.mohite@sternir.com
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Lug 2023 a Lug 2024